Savara Inc (SVRA)
5.265
+0.32
(+6.36%)
USD |
NASDAQ |
May 07, 16:00
5.265
0.00 (0.00%)
After-Hours: 17:03
Savara SG&A Expense (Quarterly): 4.852M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 4.852M |
September 30, 2023 | 4.147M |
June 30, 2023 | 3.302M |
March 31, 2023 | 3.366M |
December 31, 2022 | 3.242M |
September 30, 2022 | 2.376M |
June 30, 2022 | 2.957M |
March 31, 2022 | 2.354M |
December 31, 2021 | 3.019M |
September 30, 2021 | 3.40M |
June 30, 2021 | 3.153M |
March 31, 2021 | 2.778M |
December 31, 2020 | 2.79M |
September 30, 2020 | 5.375M |
June 30, 2020 | 3.117M |
March 31, 2020 | 2.982M |
December 31, 2019 | 3.296M |
September 30, 2019 | 2.811M |
June 30, 2019 | 4.211M |
March 31, 2019 | 2.763M |
December 31, 2018 | 3.252M |
September 30, 2018 | 3.148M |
June 30, 2018 | 2.486M |
March 31, 2018 | 1.769M |
December 31, 2017 | 2.671M |
Date | Value |
---|---|
September 30, 2017 | 1.486M |
June 30, 2017 | 5.088M |
March 31, 2017 | 1.736M |
December 31, 2016 | 0.865M |
September 30, 2016 | 1.002M |
June 30, 2016 | 0.608M |
March 31, 2016 | 2.835M |
December 31, 2015 | -6.798M |
September 30, 2015 | 2.46M |
June 30, 2015 | 2.41M |
March 31, 2015 | 3.578M |
December 31, 2014 | 2.397M |
September 30, 2014 | 2.455M |
June 30, 2014 | 2.37M |
March 31, 2014 | 2.266M |
December 31, 2013 | 2.147M |
September 30, 2013 | 2.158M |
June 30, 2013 | 2.100M |
March 31, 2013 | 2.113M |
December 31, 2012 | 1.787M |
September 30, 2012 | 1.816M |
June 30, 2012 | 1.871M |
March 31, 2012 | 2.045M |
December 31, 2011 | 1.810M |
September 30, 2011 | 1.982M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.354M
Minimum
Mar 2022
5.375M
Maximum
Sep 2020
3.344M
Average
3.153M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
NovaBay Pharmaceuticals Inc | 2.609M |
Palatin Technologies Inc | 3.033M |
iBio Inc | 2.961M |
Theriva Biologics Inc | 2.021M |
Oragenics Inc | 1.754M |